证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2022005 | --- | --- | --- | --- | --- | |-------------------------------|-----------------------------------------------------------|------------------------------------------------------|-------|-----------------------| | | | | | | | | ☐ 特定对象调研 ☐ 业绩说明会 | ☐ 分析师会议 ☐ 新闻发布会 | | ☐ 媒体采访 ☐ 路演活动 | | 投 资 者 关 系 活动类别 | ☐ 现场参观 | ☐ 一对一沟通 | | | | | ☑ 其他（ 2022 | 年广东辖区上市公司投资者集体接待日） | | | | 参 与 单 位 名 称 及 人 员 姓 | 线上参与的投资者 | | | | | 名 时间 2022 | 年 9 月 22 日下午 | 15:50-16:50 | ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2022004 | --- | --- | --- | |----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2022006 | --- | --- | --- | |----------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022007 证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ☐ 特定对象调研 | 分析师会议 ☐ 媒体采访 | | 投 资 者 关 系 | ☐ 业绩说明会 | 新闻发布会 ☐ 路演活动 | | 活动类别 | ☐ 现场参观 | 一对一沟通 ☑ 其他：电话会议 | | | | 华安证券：谭国超、钱琨、屈振静；华宝基金 王天乐；通 | | 参 ...

关于参加网上集体接待日活动的公告 证券代码：301033 证券简称：迈普医学 公告编号：2022-037 广州迈普再生医学科技股份有限公司 关于参加 2022 广东辖区上市公司投资者网上集体接待日活 动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广州迈普再生医学科技股份 有限公司（以下简称"公司"）将参加由中国证券监督管理委员会广 东监管局、广东上市公司协会共同举办的"2022 广东辖区上市公司 投资者网上集体接待日"活动。现将有关事项公告如下： 本次活动将在深圳市全景网络有限公司提供的网上平台，采取网 络 远 程 互 动 的 方 式 举 行 。 投 资 者 可 登 录 " 全 景 路 演 " 网 站 （http://rs.p5w.net）参与本次活动，网上互动交流时间为 2022 年 9 月 22 日（星期四）下午 15:50 至 16:50。 届时，公司董事长、总经理袁玉宇先生和董事、副总经理、财务 总监骆雅红女士以及董事、董事会秘书龙小燕女士将出席本次交流活 动。欢迎广大投资者积极参与。 特此公告。 广州迈普再 ...

Financial Performance - The company reported a revenue of RMB XX million for the first half of 2022, representing a YY% increase compared to the same period in 2021[14]. - The company's operating revenue for the reporting period was ¥95,024,904.82, representing a 38.24% increase compared to ¥68,737,363.88 in the same period last year[22]. - The net profit attributable to shareholders was ¥21,240,644.15, a slight increase of 1.52% from ¥20,922,582.46 year-on-year[22]. - The net profit after deducting non-recurring gains and losses decreased by 8.69% to ¥14,835,371.87 from ¥16,246,381.06 in the previous year[22]. - The company's total profit for the first half of 2022 was CNY 24,163,129.87, slightly down from CNY 24,468,274.73 in the same period last year, indicating a decrease of 1.3%[172]. - The company's total comprehensive income for the first half of 2022 was CNY 21,083,159.68, compared to CNY 20,909,768.80 in the same period of 2021, reflecting a marginal increase of 0.8%[172]. - The company's revenue for the reporting period reached ¥95,024,904.82, representing a year-on-year increase of 38.24% due to sales growth[72]. - The company's retained earnings decreased by 6,606,295.10 yuan during the reporting period, indicating a reduction in profit distribution to shareholders[195]. Assets and Liabilities - The total assets of the company as of June 30, 2022, amounted to RMB XX million, showing a ZZ% growth year-on-year[14]. - The total assets at the end of the reporting period were ¥752,304,763.44, a 0.77% increase from ¥746,569,716.44 at the end of the previous year[22]. - The total liabilities decreased to ¥162,174,315.16 from ¥170,916,132.74, reflecting a reduction in financial obligations[165]. - The company's equity attributable to shareholders increased to ¥586,676,733.24 from ¥572,042,384.19, indicating a strengthening of the company's financial position[165]. - The total equity of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. at the end of the reporting period is 578,968,492.28 yuan, an increase from 569,055,138.87 yuan at the end of the previous year, reflecting a growth of approximately 1.6%[195]. Research and Development - The company has invested in R&D, with a budget allocation of RMB XX million for the development of new technologies and products in 2022[14]. - The company maintains a strong focus on R&D, with ongoing investments to enhance its product pipeline in neurosurgery and expand into other surgical fields[43]. - The company has developed a multi-layered product R&D structure, including pre-research, development, and sales stages, to ensure continuous innovation[43]. - The company has developed multiple innovative products through a diversified core technology platform, including bio-additive manufacturing and digital design[59]. - The company has a strong R&D team of 69 people, accounting for 25% of the workforce, with 50% holding bachelor's degrees or higher[66]. Market Expansion and Strategy - The company plans to expand its market presence by launching new products in the field of regenerative medicine, focusing on innovative medical devices[14]. - The company aims to achieve a revenue growth target of AA% for the full year 2022, driven by increased sales and market expansion efforts[14]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[14]. - The company has established partnerships with nearly 600 distributors and its products are now available in over 1,200 hospitals domestically, with international market coverage in 80 countries and regions[37][38]. - The company is committed to enhancing brand recognition and market penetration through targeted training and academic promotion initiatives[42]. Quality and Compliance - The company is committed to maintaining high standards of product quality and safety, as evidenced by its compliance with CE certification requirements for its medical devices[14]. - The company emphasizes quality management throughout its production process, adhering to industry regulations and internal quality control systems[36]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[4]. - The company reported a profit distribution plan for 2021, distributing a cash dividend of RMB 1.00 per 10 shares to all shareholders[114]. - The company has no significant asset or equity sales during the reporting period[90]. - The company has no fundraising activities during the reporting period[86]. Risks and Challenges - The management highlighted potential risks in the market, including regulatory changes and competition, and outlined strategies to mitigate these risks[3]. - The company faces risks related to new product development, including potential delays in product registration and market launch[93]. - The company is subject to risks from policy changes in the high-value medical device industry, which could adversely affect its operations[96]. Operational Insights - The company is closely monitoring the COVID-19 situation and preparing response plans to mitigate operational risks[101][102]. - The company has established a complete industrialization system for technology research and development, registration, and production transformation[99]. - The company has not reported any new product launches or technological advancements in this period, focusing instead on maintaining existing operations[195].

Financial Performance - The company's revenue for Q1 2022 was ¥37,272,422.06, representing a 14.63% increase compared to ¥32,515,128.53 in the same period last year[4] - Net profit attributable to shareholders decreased by 31.07% to ¥7,165,807.56 from ¥10,395,879.49 year-on-year[4] - The net profit after deducting non-recurring gains and losses fell by 43.84% to ¥4,315,963.53 compared to ¥7,684,495.43 in the previous year[4] - Basic and diluted earnings per share decreased by 47.62% to ¥0.11 from ¥0.21 year-on-year[6] - Net profit for the current period was ¥7,156,332.03, a decrease from ¥10,388,539.49, reflecting a decline of approximately 30%[31] - Earnings per share (EPS) for the current period was ¥0.11, down from ¥0.21 in the previous period, showing a decrease of about 47.6%[32] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥2,353,328.55, a decline of 139.60% from ¥5,942,226.22 in the same period last year[4] - Cash inflow from investment activities was ¥294,610,819.98, compared to ¥210,867,036.80 in the previous period, marking an increase of approximately 39.7%[36] - The company's cash and cash equivalents at the end of the period were CNY 8,351,208.16, a decrease from CNY 10,351,875.86 at the beginning of the year, representing a decline of about 19.3%[21] - The net increase in cash and cash equivalents was -2,000,667.70, a significant decline from 4,616,112.41 in the previous period[38] Expenses - Research and development expenses rose by 56.80% to ¥5,619,822.65, driven by increased project costs[11] - The company reported a 55.58% increase in sales expenses, totaling ¥13,081,301.03, primarily due to higher business promotion costs[11] - Total operating costs amounted to ¥32,254,453.36, up from ¥23,426,120.45, indicating a rise of about 37.5%[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,067[14] - The top two shareholders, Yuan Yuyu and Xu Tao, each hold 16.53% of the shares, totaling 10,922,547 shares[14] - The company has a total of 4,508,796 shares held by Yuan Meifu, representing 6.82% of the shares[14] - The company has 4,246,049 shares held by Shenzhen Kaiyingke Technology Co., Ltd., accounting for 6.43% of the shares[14] - The company has a total of 3,267,436 shares held by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, representing 4.95% of the shares[14] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder holding 16.53%[14] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥725,056,387.22, down 2.88% from ¥746,569,716.44 at the end of the previous year[6] - The company reported a total asset of CNY 725,056,387.22 as of March 31, 2022, down from CNY 746,569,716.44 at the beginning of the year, indicating a decrease of approximately 2.3%[25] - The total current assets decreased to CNY 374,706,437.62 from CNY 417,142,182.84, reflecting a reduction of approximately 10.1%[23] - The total liabilities decreased from CNY 170,916,132.74 to CNY 142,246,471.49, reflecting a decline of about 16.9%[25] - The company’s long-term borrowings remained stable at CNY 101,673,625.45, unchanged from the previous period[25] - The company’s equity position is strengthened as total liabilities decreased while total assets also saw a reduction, indicating improved financial stability[25] Investments - Investment income increased by 52.15% to ¥2,179,943.38, attributed to higher financial management returns[11] - The company invested GBP 100,000 in UK-based Reco Medical Ltd, acquiring a 5.01% stake, which aligns with its strategic focus on neurosurgery[19] Certification and Audit - The company has successfully passed the high-tech enterprise certification again, which positively impacts its brand image and market value[18] - The company’s first quarter report was not audited[39]

Financial Performance - The company's operating revenue for 2021 was CNY 153,785,686.53, representing a 24.51% increase compared to CNY 123,511,821.40 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 44,733,830.57, up 21.01% from CNY 36,967,815.22 in 2020[19]. - The net cash flow from operating activities increased by 96.15% to CNY 66,510,692.29 in 2021, compared to CNY 33,908,754.88 in 2020[19]. - The total assets at the end of 2021 reached CNY 746,569,716.44, a 66.67% increase from CNY 447,939,659.82 at the end of 2020[19]. - The net assets attributable to shareholders increased by 70.25% to CNY 572,042,384.19 at the end of 2021, compared to CNY 335,995,919.55 at the end of 2020[19]. - The company reported a basic earnings per share of CNY 0.79 for 2021, a 5.33% increase from CNY 0.75 in 2020[19]. - The company received government subsidies amounting to CNY 18,323,115.13 in 2021, compared to CNY 12,793,230.48 in 2020[24]. - The company reported a total revenue of 1.2 billion RMB for the year 2021, reflecting a year-on-year growth of 15%[148]. - The company reported a total R&D investment of ¥41,658,606.43 in 2021, representing 27.09% of its operating revenue[81]. Market Position and Strategy - The company is focused on expanding its market presence and developing new products, particularly in the field of regenerative medicine and medical devices[4]. - The company aims to become a leading enterprise in high-performance implantable medical devices in the neurosurgery field and plans to extend its technology platform to oral and other surgical fields[35]. - The company is positioned to benefit from the increasing health demands and the rapid growth of the medical device industry in China[30]. - The company has established a global marketing network, collaborating with nearly 600 distributors and covering over 70 countries and regions[45]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[164]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for this purpose[148]. - The company aims to increase its market share by leveraging innovative products and technologies in the healthcare sector[154]. Research and Development - The company is actively involved in research and development of new technologies, including bio-additive manufacturing and advanced biomaterials[13]. - The company has a robust R&D team responsible for technology development, ensuring a steady pipeline of new products and technologies[46]. - The company has established a multi-layered product research and development layout, focusing on continuous innovation to enhance market competitiveness[51]. - The company reported a total R&D expenditure for 2021 was 150 million yuan, accounting for 12.5% of total revenue, aimed at developing new medical technologies[164]. - The company is in the registration process for two new Class III products, including an absorbable medical adhesive and a PEEK craniofacial repair system[83]. Product Development and Innovation - The company has developed a series of innovative products using advanced manufacturing technologies, including a craniofacial repair product based on PEEK material, which is already sold in multiple countries[37]. - The absorbable medical glue is currently under review for registration and is expected to be the first of its kind produced by a listed company in A-shares if approved[35]. - The company has obtained domestic medical device registration for its absorbable regenerated cellulose hemostatic product, enhancing its product portfolio and market competitiveness[35]. - The company has developed multiple innovative products using advanced manufacturing technologies, including absorbable hard brain (spinal) membrane patches with a unique three-dimensional biomimetic structure[55]. Governance and Management - The company has established a complete and independent business system, ensuring operational independence from its controlling shareholders and actual controllers[134]. - The board of directors consists of 9 members, including 3 independent directors, meeting legal and regulatory requirements[135]. - The company has implemented a performance evaluation and incentive mechanism, ensuring transparency in the appointment of senior management[136]. - The company has established a remuneration and assessment committee to oversee the compensation plans for directors and senior management[167]. - The company emphasizes strict quality management throughout the production process, adhering to industry regulations and internal quality systems[43]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, indicating potential risks and countermeasures in its operations[4]. - The company faces risks related to new product development and technology iteration, requiring continuous innovation to maintain competitiveness[119]. - The company is closely monitoring the impact of recurring COVID-19 outbreaks, which have affected global economic operations and normal medical services, potentially impacting its business operations[126]. - The company is preparing response plans to address risks and challenges posed by the pandemic[127]. Employee Development - The company emphasizes employee development and has established a reasonable bonus incentive plan to boost R&D and sales efforts[184]. - The total number of employees at the end of the reporting period was 271, with 264 from the parent company and 7 from major subsidiaries[182]. - The company conducted over 350 internal training sessions in 2021, focusing on R&D, quality, systems, and production[185]. - The company has a total of 6 employees with a PhD and 26 with a Master's degree, reflecting a strong educational background among staff[182]. Profit Distribution - The company reported a profit distribution plan to distribute a cash dividend of 1.00 RMB per 10 shares (including tax) to all shareholders, based on 66,062,951 shares[4]. - The company has a policy to prioritize cash dividends when conditions for cash distribution are met[190]. - The company plans to distribute at least 10% of the distributable profits as cash dividends if there are no major investment plans or cash expenditures[191].

Financial Performance - The company's operating revenue for Q3 2021 was ¥34,601,672.19, representing an increase of 18.26% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥11,124,808.29, up 47.37% year-on-year[3]. - The net profit excluding non-recurring gains and losses was ¥5,665,964.09, a decrease of 2.65% compared to the previous year[5]. - Basic earnings per share for the period were ¥0.18, an increase of 20.00% compared to the same period last year[5]. - Total operating revenue for the third quarter reached ¥103,339,036.07, an increase of 26.5% compared to ¥81,615,603.08 in the previous year[37]. - Net profit for the period was ¥32,030,335.22, representing a 39% increase from ¥23,056,678.07 in the prior year[38]. - Basic and diluted earnings per share increased to 0.60 from 0.47, representing a growth of 27.66% year-over-year[41]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥720,354,591.75, reflecting a 60.82% increase from the end of the previous year[5]. - Total liabilities increased to ¥157,371,961.84, compared to ¥108,299,999.20 in the previous year, marking a growth of 45.2%[35]. - The total assets of the company reached ¥720,354,591.75, a significant rise from ¥447,939,659.82 year-over-year[33]. - Total current liabilities include accounts payable of 36,646,732.31 and employee compensation payable of 11,090,491.46[52]. Cash Flow - The company's cash flow from operating activities was ¥31,259,323.68, showing a significant increase of 230.85% year-to-date[5]. - Operating cash flow net amount reached 31,259,323.68, up from 9,448,316.70, marking a significant increase of 230.56%[44]. - Total cash inflow from operating activities was 132,688,343.01, compared to 97,253,561.79 in the previous period, reflecting a growth of 36.48%[42]. - Cash outflow from operating activities totaled 101,429,019.33, an increase from 87,805,245.09, which is a rise of 15.43%[44]. - Cash flow from financing activities netted 248,377,268.52, a substantial increase from 20,955,980.62, indicating a growth of 1,184.09%[46]. - The ending balance of cash and cash equivalents was 50,235,962.38, up from 28,852,233.41, showing an increase of 74.48%[46]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,382[14]. - Major shareholders include Yuan Yuyu and Xu Tao, each holding 16.53% (10,922,547 shares) of the company[14]. - The company has a total of 4,508,796 shares held by Yuan Meifu, representing 6.82% of the total shares[14]. - The report indicates that the total number of shares with limited sale conditions is 10,922,547 for both Yuan Yuyu and Xu Tao, set to be released on July 26, 2024[20]. - The report highlights that the company is actively managing its shareholder structure and compliance with regulations regarding share sales[19]. Government Support and Funding - The company received government subsidies amounting to ¥1,855,383.01 during the reporting period, which are closely related to its normal business operations[7]. - The company raised a total of RMB 250,048,697.24 from its initial public offering (IPO), with a net amount of RMB 192,877,550.38 after deducting related expenses[25]. - The company adjusted the planned use of raised funds, reducing the investment in the headquarters project from RMB 360,000,000.00 to RMB 172,877,550.38[25]. - Cumulative use of raised funds reached RMB 164,446,780.95, with a remaining balance of RMB 28,609,298.47 in the dedicated account[26]. Research and Development - Research and development expenses increased to ¥14,068,497.76, compared to ¥11,706,352.06 in the previous year, reflecting a growth of 20.2%[38]. - The company plans to allocate RMB 20,000,000.00 for the development of new implantable medical devices[25]. - The company has successfully obtained domestic medical device registration for its absorbable regenerated oxidized cellulose hemostatic product, enhancing its product portfolio and market competitiveness[27]. - The company’s strategic focus on expanding its product applications in the neurosurgery field, aiming to break the long-standing import monopoly in this market[27]. Strategic and Operational Insights - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[34]. - The company’s financial adjustments reflect a proactive approach to align its funding with operational needs and market opportunities[25]. - The report does not indicate any new product launches or technological advancements during this period[21]. - There is no mention of market expansion or mergers and acquisitions in the current report[21]. - The company has not provided a detailed future outlook or performance guidance in the current report[56].

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20% compared to the same period in 2020[15]. - The company's operating revenue for the reporting period was ¥68,737,363.88, representing a 31.28% increase compared to ¥52,357,552.44 in the same period last year[21]. - The net profit attributable to shareholders was ¥20,922,582.46, up 34.24% from ¥15,585,961.43 year-on-year[21]. - The net cash flow from operating activities increased by 237.47%, reaching ¥20,713,772.53 compared to ¥6,137,963.71 in the previous year[21]. - The total profit for the first half of 2021 was ¥24,468,274.73, a 36.2% increase from ¥18,006,018.54 in the first half of 2020[178]. - The company reported a significant increase in financing activities, with net cash flow from financing activities rising by 235.97% to ¥43,896,562.01, primarily due to increased bank borrowings[72]. - The company’s cash flow from operating activities showed a strong performance, with total cash inflow increasing by 37% year-over-year, from CNY 74,673,319.23 to CNY 87,677,760.53[188]. Product Development and Innovation - The company plans to expand its product line by introducing three new medical devices by the end of 2021, targeting a market share increase of 15% in the next year[15]. - The company has developed a series of innovative products, including a bio-absorbable dura mater patch, which is the only brain membrane product listed in the Ministry of Science and Technology's "Innovative Medical Device Product Directory (2018)"[30]. - The company has established a product pipeline with 8 products in development, 3 of which are in the registration or clinical trial stages, indicating a strong focus on innovation[43]. - The company has developed high-performance implantable medical devices using core technologies such as bio-additive manufacturing and digital design, enhancing product performance and market competitiveness[40]. - The company has developed a bio-absorbable dura (spinal) patch, which is the first of its kind in China to apply bio-additive manufacturing technology, addressing challenges in traditional processing methods[55]. Market Position and Strategy - Future guidance estimates a revenue growth of 30% for the full year 2021, driven by increased demand in the domestic market[15]. - The company is exploring potential mergers and acquisitions to enhance its market presence and expand its product offerings[15]. - The company has established partnerships with over 500 distributors and its products are available in over 800 hospitals domestically[34]. - The company has a global marketing network covering over 70 countries and regions, including Europe, South America, Asia, and Africa[34]. - The company aims to become a platform-type enterprise by expanding its product line through R&D and acquisitions, enhancing its market presence and risk resilience[52]. Financial Health and Assets - The total assets at the end of the reporting period were ¥508,833,601.47, a 13.59% increase from ¥447,939,659.82 at the end of the previous year[21]. - Cash and cash equivalents increased to ¥25,368,613.14, representing 4.99% of total assets, up from 2.61% last year, a growth of 2.38%[79]. - The company reported a total of ¥31,260,000 in entrusted financial management, with an outstanding balance of ¥19,710,000[89]. - Long-term borrowings rose significantly to ¥92,920,819.25, representing 18.26% of total assets, an increase of 7.66% from 10.60% last year, primarily for the construction of the headquarters project[79]. - The company reported a decrease in accounts payable to CNY 25.78 million, down from CNY 36.65 million, a reduction of approximately 29.8%[170]. Research and Development - The company has allocated RMB 20 million for research and development in new technologies, focusing on bio-materials and 3D printing applications[15]. - Research and development expenses rose by 28.10% to ¥15,219,936.45, reflecting the company's commitment to innovation[72]. - The company focuses on independent research and development, with a dedicated R&D center overseeing technology development[36]. - The company has implemented a strict quality management system throughout its production process to ensure product safety and traceability[35]. Risks and Challenges - The company has identified key risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[4]. - The company faces risks in new product development, including potential delays in regulatory approvals that could impact operational performance[95]. - The company faces risks from policy changes in the high-value medical device industry, which could adversely affect its operations[97]. Shareholder Information - The company issued 16,515,766 shares at an issuance price of ¥15.14 per share, increasing the total share capital from 49,547,185 shares to 66,062,951 shares[22]. - Major shareholders include Yuan Yuyu and Xu Tao, each holding 10,922,547 shares, which will be released in 2024[145]. - The total number of common shareholders at the end of the reporting period is 20,523[152]. Compliance and Governance - The company and its subsidiaries complied with environmental protection laws and did not face any penalties for violations during the reporting period[112]. - There were no significant lawsuits or arbitration matters during the reporting period[121]. - The half-year financial report was not audited[119].